Last reviewed · How we verify
Venlafaxine 37.5 MG
At a glance
| Generic name | Venlafaxine 37.5 MG |
|---|---|
| Also known as | SNRI analgesia |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Physiologic Monitoring of Antidepressant Response (PHASE4)
- Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder (PHASE4)
- The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement (PHASE4)
- REDucing Hot FLASHes in Women Using Endocrine Therapy. (PHASE3)
- Mood Disorders in Head and Neck Cancer Patients (PHASE4)
- Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes (PHASE2, PHASE3)
- Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer (PHASE2)
- Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venlafaxine 37.5 MG CI brief — competitive landscape report
- Venlafaxine 37.5 MG updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI